88 related articles for article (PubMed ID: 10622045)
61. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
[TBL] [Abstract][Full Text] [Related]
62. The picture of future therapy.
Gazzard B
Int J Clin Pract Suppl; 1999 Jun; 103():45-8. PubMed ID: 10622045
[TBL] [Abstract][Full Text] [Related]
63. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
64. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
65. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
66. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
67. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
68. Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.
Barreiro P; García-Benayas T; Soriano V; Gallant J
AIDS Rev; 2002; 4(4):233-41. PubMed ID: 12555697
[TBL] [Abstract][Full Text] [Related]
69. Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
Waters LJ; Nelson MR
Int J Clin Pract; 2005 Dec; 59(12):1452-8. PubMed ID: 16351678
[TBL] [Abstract][Full Text] [Related]
70. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
[TBL] [Abstract][Full Text] [Related]
71. HIV protease inhibitors: pharmacologic and metabolic distinctions.
Sommadossi JP
AIDS; 1999 Sep; 13 Suppl 1():S29-40. PubMed ID: 10546783
[TBL] [Abstract][Full Text] [Related]
72. Positioning of HIV-protease inhibitors in clinical practice.
Andreoni M; Perno CF
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):10-8. PubMed ID: 22338543
[TBL] [Abstract][Full Text] [Related]
73. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.
Shafer RW; Vuitton DA
Biomed Pharmacother; 1999 Mar; 53(2):73-86. PubMed ID: 10337461
[TBL] [Abstract][Full Text] [Related]
74. Switch studies: a review.
Murphy RL; Smith WJ
HIV Med; 2002 Apr; 3(2):146-55. PubMed ID: 12010362
[TBL] [Abstract][Full Text] [Related]
75. Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity.
Blas-Garcia A; Esplugues JV; Apostolova N
Curr Med Chem; 2011; 18(14):2186-95. PubMed ID: 21521162
[TBL] [Abstract][Full Text] [Related]
76. [Antiretroviral treatment of HIV infection in children].
Ramos Amador JT; Saavedra Lozano J; de José Gómez MI
An Esp Pediatr; 1998 May; 48(5):456-69. PubMed ID: 9656531
[No Abstract] [Full Text] [Related]
77. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens.
Vanangamudi M; Kurup S; Namasivayam V
Curr Opin Pharmacol; 2020 Oct; 54():179-187. PubMed ID: 33202360
[TBL] [Abstract][Full Text] [Related]
78. [Therapeutic strategies for HIV infection: redefining simplification].
Raffi F
Med Mal Infect; 2004 Nov; 34 Suppl 3():S223-8. PubMed ID: 15906446
[TBL] [Abstract][Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
